Published online Jul 16, 2022. doi: 10.12998/wjcc.v10.i20.6915
Peer-review started: September 6, 2021
First decision: November 7, 2021
Revised: November 11, 2021
Accepted: April 21, 2022
Article in press: April 21, 2022
Published online: July 16, 2022
Processing time: 301 Days and 18.8 Hours
Endoscopic submucosal dissection (ESD) for the treatment of early signet ring cell carcinoma (SRC) is controversial.
SRC may represent an indication for ESD. Nevertheless, ESD for SRC early gastric cancer (EGC) remains debatable. Therefore, a meta-analysis was carried out for assessing the clinical outcomes of ESD for undifferentiated (UD) SRC EGC cases.
This work aimed to meta-analyzed reports evaluating the therapeutic efficacy and safety of ESD in early SRC gastric cancer.
The PubMed, Web of Science, Cochrane Library, and EMBASE databases were searched for relevant reports evaluating the efficacy and safety of ESD for treating SRC.
The total lymphovascular invasion and en bloc resection rates were 3.8% and 98.4%, respectively. The total complete and incomplete resection rates were estimated at 78.5% and 18.8%, respectively. The total procedure-associated gastric hemorrhage and perforation rates were 2.6% and 0.4%, respectively. The curative resection, vertical margin invasion, and lateral margin invasion rates were 72.1%, 2.3%, and 34.45%, respectively.
ESD represents a promising therapeutic approach for UD SRC EGC. Further improvements are required to increase treatment efficacy and reduce adverse outcomes.
ESD as a treatment tool constitutes a critical step in improving daily clinical practice associated with SRC EGC. Future trials with a larger sample size and longer follow-up duration are warranted to evaluate the long-term efficacy and safety of ESD treatment for SRC EGC.